*The following content is generated by AI and is for reference only.
Enzalutamide is a potent, non-steroidal anti-androgen agent primarily utilized in the treatment of prostate cancer. With the chemical formula C26H20F3N7O and CAS registry number 1048926-65-1, this small molecule functions by selectively binding to the androgen receptor (AR) with high affinity. Unlike traditional anti-androgens that merely block ligand binding, Enzalutamide exerts a multi-modal mechanism of action. It competitively inhibits the binding of endogenous androgens like testosterone and dihydrotestosterone to the AR, prevents the nuclear translocation of the receptor, and blocks its interaction with DNA. Furthermore, it suppresses the recruitment of co-activators essential for transcriptional activity, effectively halting the proliferation of cancer cells driven by androgen signaling.
Clinically, Enzalutamide is indicated for castration-resistant prostate cancer (CRPC), both in patients who have previously received chemotherapy and in those who are chemotherapy-naïve. It has also demonstrated efficacy in metastatic hormone-sensitive prostate cancer when combined with standard androgen deprivation therapy. The drug is administered orally as a capsule, offering significant convenience for long-term management. Common side effects include fatigue, hypertension, hot flashes, and an increased risk of seizures, necessitating careful patient monitoring. As a cornerstone in modern oncology, Enzalutamide has significantly improved progression-free survival and overall survival rates for men suffering from advanced prostate malignancies. Its development marked a paradigm shift in targeting the androgen pathway, providing a critical therapeutic option where other treatments may fail. Ongoing research continues to explore its potential in earlier disease stages and combination regimens to further optimize clinical outcomes and manage resistance mechanisms.